Intellia Therapeutics, Inc. Peer Comparison
Metric | Value | Ranking | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $968.6 Million | 4/10 | VRTX $117.2B |
CRSP $3.7B |
BEAM $2.4B |
NTLA $968.6M |
DNA $708.1M |
VERV $661.2M |
SANA $634.1M |
FATE $142.4M |
CRBU $116.8M |
EDIT $98.2M |
Gross Margin | 100% | 1/10 | NTLA 100% |
FATE 100% |
CRBU 100% |
DNA 89% |
VRTX 86% |
VERV 74% |
BEAM 62% |
SANA 0% |
EDIT -100% |
CRSP -100% |
Profit Margin | -100% | 4/10 | VRTX 38% |
SANA 0% |
DNA -63% |
NTLA -100% |
EDIT -100% |
FATE -100% |
CRSP -100% |
BEAM -100% |
CRBU -100% |
VERV -100% |
EBITDA margin | -1490% | 6/10 | VRTX 40% |
DNA -62% |
SANA -100% |
BEAM -639% |
VERV -829% |
NTLA -1490% |
FATE -1704% |
CRBU -1889% |
CRSP -18294% |
EDIT -101870% |
Quarterly Revenue | $9.1 Million | 4/10 | VRTX $2.8B |
DNA $89.0M |
BEAM $14.3M |
NTLA $9.1M |
VERV $6.9M |
FATE $3.1M |
CRBU $2.0M |
CRSP $602,000 |
EDIT $61,000 |
SANA $0 |
Quarterly Earnings | -$135.7 Million | 10/10 | VRTX $1.0B |
CRBU -$34.7M |
FATE -$47.7M |
VERV -$50.1M |
DNA -$56.4M |
SANA -$59.9M |
EDIT -$62.1M |
CRSP -$85.9M |
BEAM -$96.7M |
NTLA -$135.7M |
Quarterly Free Cash Flow | -$86.1 Million | 7/10 | VRTX $1.5B |
FATE -$29.9M |
CRBU -$33.3M |
VERV -$40.5M |
EDIT -$55.5M |
SANA -$55.9M |
NTLA -$86.1M |
BEAM -$89.7M |
CRSP -$107.1M |
DNA -$118.6M |
Trailing 4 Quarters Revenue | $43.1 Million | 6/10 | VRTX $10.6B |
BEAM $349.6M |
DNA $218.0M |
CRSP $201.6M |
EDIT $61.8M |
NTLA $43.1M |
VERV $24.4M |
FATE $13.4M |
CRBU $11.5M |
SANA $0 |
Trailing 4 Quarters Earnings | -$522.3 Million | 9/10 | VRTX $2.8B |
DNA $89.0M |
BEAM $14.3M |
NTLA $9.1M |
VERV $6.9M |
FATE $3.1M |
CRBU $2.0M |
CRSP $602,000 |
EDIT $61,000 |
SANA -$0 |
Quarterly Earnings Growth | -11% | 7/10 | DNA 81% |
CRSP 23% |
VRTX 1% |
BEAM -1% |
FATE -6% |
VERV -10% |
NTLA -11% |
EDIT -38% |
CRBU -247% |
SANA -6190% |
Annual Earnings Growth | -6% | 7/10 | BEAM 58% |
CRSP 31% |
DNA 21% |
SANA 10% |
FATE 8% |
VERV 5% |
NTLA -6% |
EDIT -27% |
CRBU -50% |
VRTX -113% |
Quarterly Revenue Growth | -24% | 9/10 | VERV 120% |
DNA 61% |
FATE 58% |
VRTX 12% |
EDIT 0% |
CRSP 0% |
SANA 0% |
BEAM -17% |
NTLA -24% |
CRBU -91% |
Annual Revenue Growth | -18% | 8/10 | EDIT 613% |
BEAM 351% |
FATE 184% |
VERV 160% |
VRTX 7% |
SANA 0% |
CRSP -4% |
NTLA -18% |
DNA -27% |
CRBU -67% |
Cash On Hand | $120.5 Million | 7/10 | VRTX $5.2B |
DNA $616.2M |
BEAM $230.2M |
CRSP $225.7M |
VERV $158.7M |
SANA $127.0M |
NTLA $120.5M |
EDIT $95.8M |
FATE $37.9M |
CRBU $32.0M |
Short Term Debt | $19.2 Million | 1/10 | NTLA $19.2M |
CRSP $16.9M |
EDIT $16.4M |
BEAM $12.9M |
SANA $10.6M |
VERV $10.4M |
FATE $6.9M |
CRBU $1.2M |
VRTX -$0 |
DNA -$0 |
Long Term Debt | $82.4 Million | 7/10 | VRTX $1.7B |
DNA $445.6M |
BEAM $298.3M |
CRSP $210.7M |
FATE $92.1M |
SANA $85.5M |
NTLA $82.4M |
VERV $60.9M |
CRBU $25.5M |
EDIT $22.1M |
PE | -1.00 | 1/10 | NTLA -1.00 |
VRTX -1.00 |
EDIT -1.00 |
FATE -1.00 |
CRSP -1.00 |
BEAM -1.00 |
SANA -1.00 |
CRBU -1.00 |
VERV -1.00 |
DNA -1.00 |
PS | 22.48 | 2/10 | VERV 27.10 |
NTLA 22.48 |
CRSP 18.33 |
VRTX 11.05 |
FATE 10.59 |
CRBU 10.18 |
BEAM 6.77 |
DNA 3.25 |
EDIT 1.59 |
SANA -1.00 |
PB | 1.01 | 6/10 | VRTX 7.50 |
BEAM 2.99 |
SANA 2.17 |
CRSP 1.91 |
VERV 1.30 |
NTLA 1.01 |
DNA 0.89 |
EDIT 0.56 |
CRBU 0.42 |
FATE 0.39 |
PC | 8.04 | 4/10 | VRTX 22.38 |
CRSP 16.38 |
BEAM 10.28 |
NTLA 8.04 |
SANA 4.99 |
VERV 4.17 |
FATE 3.76 |
CRBU 3.65 |
DNA 1.15 |
EDIT 1.03 |
Liabilities to Equity | 0.22 | 8/10 | SANA 0.91 |
EDIT 0.87 |
DNA 0.86 |
BEAM 0.48 |
VRTX 0.42 |
FATE 0.37 |
VERV 0.31 |
NTLA 0.22 |
CRBU 0.22 |
CRSP 0.16 |
ROA | -0.45 | 8/10 | VRTX -2% | CRSP -11% | BEAM -12% | VERV -30% | FATE -38% | CRBU -43% | DNA -44% | NTLA -45% | SANA -55% | EDIT -64% |
ROE | -0.54 | 7/10 | VRTX -3% |
CRSP -12% |
BEAM -18% |
VERV -39% |
FATE -52% |
CRBU -53% |
NTLA -54% |
DNA -82% |
SANA -105% |
EDIT -120% |
Current Ratio | 5.57 | 2/10 | CRSP 7.13 |
NTLA 5.57 |
CRBU 5.45 |
VERV 4.27 |
FATE 3.73 |
VRTX 3.36 |
BEAM 3.08 |
DNA 2.17 |
EDIT 2.16 |
SANA 2.10 |
Quick Ratio | 3.12 | 4/10 | NTLA -1.00 |
VRTX -1.00 |
EDIT -1.00 |
FATE -1.00 |
CRSP -1.00 |
BEAM -1.00 |
SANA -1.00 |
CRBU -1.00 |
VERV -1.00 |
DNA -1.00 |
Long Term Debt to Equity | 0.09 | 9/10 | DNA} 0.56 |
BEAM} 0.38 |
SANA} 0.29 |
FATE} 0.25 |
EDIT} 0.13 |
VERV} 0.12 |
VRTX} 0.11 |
CRSP} 0.11 |
NTLA} 0.09 |
CRBU} 0.09 |
Debt to Equity | 0.11 | 8/10 | DNA 0.56 |
SANA 0.33 |
FATE 0.27 |
EDIT 0.22 |
BEAM 0.20 |
VERV 0.14 |
CRSP 0.12 |
NTLA 0.11 |
VRTX 0.11 |
CRBU 0.09 |
Burn Rate | 0.84 | 8/10 | DNA 8.30 |
VERV 2.88 |
CRSP 2.29 |
BEAM 2.06 |
SANA 1.92 |
EDIT 1.43 |
CRBU 0.89 |
NTLA 0.84 |
FATE 0.71 |
VRTX -5.36 |
Cash to Cap | 0.12 | 7/10 | EDIT 0.98 |
DNA 0.87 |
FATE 0.27 |
CRBU 0.27 |
VERV 0.24 |
SANA 0.20 |
NTLA 0.12 |
BEAM 0.10 |
CRSP 0.06 |
VRTX 0.04 |
CCR | 0.63 | 9/10 | DNA 2.10 |
VRTX 1.43 |
CRSP 1.25 |
CRBU 0.96 |
BEAM 0.93 |
SANA 0.93 |
EDIT 0.89 |
VERV 0.81 |
NTLA 0.63 |
FATE 0.63 |
EV to EBITDA | -7.00 | 6/10 | VRTX} 101.86 |
EDIT} -0.66 |
SANA} -1.00 |
CRBU} -2.92 |
FATE} -3.88 |
NTLA} -7.00 |
DNA} -9.74 |
VERV} -10.08 |
BEAM} -25.20 |
CRSP} -33.58 |
EV to Revenue | 22.04 | 2/10 | VERV 23.52 |
NTLA 22.04 |
CRSP 18.34 |
FATE 15.13 |
VRTX 10.72 |
CRBU 9.72 |
BEAM 6.57 |
DNA 2.47 |
EDIT 0.66 |
SANA -1.00 |